Elevating the Treatment of Cancer

The Summit Is Clear

once you pass through the clouds

We believe that every patient deserves to know what is driving the growth of their cancer and how best to treat it


Elevating precision medicine to the forefront of every cancer treatment journey

Our vision is a future in which each tumor’s unique genomic test result can be matched with a purpose-built precision medicine.

Together with our drug and diagnostic developer peers, we work to enable a personalized treatment plan for each individual patient with cancer.

Our Focus

Genomic testing illuminates the path

Your tumor has a genomic fingerprint that may help your physician map the best path to overcoming it.

We advocate for every patient to get their tumor genomically tested. Only through testing can we give patients their best chance at improved outcomes.

Learn More About Genomic Testing Patient-Doctor Discussion Guide

Blazing the trail to make genomic test results actionable

We develop drugs to inhibit the specific alterations that have been identified as drivers of cancer ⏤ no matter how rare.

Our lead drug candidate, seribantumab, inhibits tumor growth driven by NRG1 gene fusions. Seribantumab is being studied in CRESTONE, a Phase 2 trial for patients with solid tumors of any origin that test positive for an NRG1 fusion.

Learn More About CRESTONE

Assembling the team


Our first journey at Elevation Oncology is the Phase 2 CRESTONE study, leading straight towards our first summit: NRG1 fusions. The tumor-agnostic approach we’ve chosen is non-traditional, but we’ve assembled a team of collaborators capable of blazing the trail and developing the tools and techniques that will smooth the way for the next summits to follow.

Read the full letter 

NOVEMBER 18, 2020

Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer